Home/Filings/4/0001209191-23-014442
4//SEC Filing

Stark David Matthew 4

Accession 0001209191-23-014442

CIK 0000818686other

Filed

Mar 1, 7:00 PM ET

Accepted

Mar 2, 7:38 AM ET

Size

15.4 KB

Accession

0001209191-23-014442

Insider Transaction Report

Form 4
Period: 2023-02-28
Stark David Matthew
Exec. VP Chief Legal Officer
Transactions
  • Exercise/Conversion

    Restricted Share Units

    2023-02-2844,9530 total
    Ordinary Shares (44,953 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2023-02-28+18,43021,404.39 total
  • Exercise/Conversion

    Ordinary Shares

    2023-02-28+44,95347,927.39 total
  • Sale

    Ordinary Shares

    2023-02-28$9.89/sh44,953$444,4322,974.39 total
  • Exercise/Conversion

    Restricted Share Units

    2023-02-2818,43018,430 total
    Ordinary Shares (18,430 underlying)
  • Sale

    Ordinary Shares

    2023-02-28$9.89/sh18,430$182,2102,974.39 total
Footnotes (6)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F5]Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 18,430 vesting on February 28, 2024.
  • [F6]Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001722360

Filing Metadata

Form type
4
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 7:38 AM ET
Size
15.4 KB